A61K 40/4269
Ny-eso
Official title: {ny-eso}
A61K40/4269 (Ny-eso) appears on 172 US grants and 388 published applications in this corpus.
Search patents in A61K- Granted patents
- 172
- Published applications
- 388
- Assignees
- 167
- Inventors
- 675
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 2 | 0 |
| 2002 | 0 | 2 |
| 2003 | 2 | 4 |
| 2004 | 0 | 8 |
| 2005 | 0 | 1 |
| 2006 | 1 | 1 |
| 2007 | 2 | 0 |
| 2008 | 0 | 1 |
| 2009 | 2 | 4 |
| 2010 | 0 | 9 |
| 2011 | 2 | 1 |
| 2012 | 1 | 2 |
| 2013 | 1 | 1 |
| 2014 | 3 | 7 |
| 2015 | 1 | 4 |
| 2016 | 2 | 6 |
| 2017 | 2 | 19 |
| 2018 | 12 | 19 |
| 2019 | 4 | 33 |
| 2020 | 14 | 19 |
| 2021 | 19 | 31 |
| 2022 | 17 | 66 |
| 2023 | 17 | 46 |
| 2024 | 15 | 41 |
| 2025 | 30 | 35 |
| 2026 | 23 | 28 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- T cell receptors and methods of use thereof28 Jul 2026US 12,692,296 B2University Health Network
- Peptide markers to track genetically engineered cells21 Jul 2026US 12,686,708 B2Neogene Therapeutics B.V.
- NR4A-deficient cells expressing c-Jun and uses thereof14 Jul 2026US 12,679,879 B2Lyell Immunopharma, Inc.
- Engineered T cell receptors and methods of use7 Jul 2026US 12,673,980 B2Board of Regents, The University of Texas System
- Plasmacytoid dendritic cells for treating cancer17 Sep 2026US 2026/0272977 A1Pdc Line Pharma
- Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof17 Sep 2026US 2026/0274962 A1Regeneron Pharmaceuticals, Inc.
- Il-9r signaling compositions and methods10 Sep 2026US 2026/0263516 A1The Regents of the University of California
- Plasmacytoid dendritic cells and immune checkpoint inhibitor for cancer treatment13 Aug 2026US 2026/0232798 A1Pdc Line Pharma
- Combination Adoptive Immune Cell and Anti-CD47 Therapy and Related Compositions6 Aug 2026US 2026/0224620 A1
Most cited
By later US patents
- Expression vectors encoding epitopes of target-associated antigens and methods for their design43US 8,252,916 B2MannKind Corporation · 2012
- Targeted disruption of T cell receptor genes using talens38US 9,937,207 B2Ospedale San Raffaele S.R.L. · 2018
- Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood25US 10,544,392 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2020
- MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-123US 7,619,057 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2009
- Variant libraries of the immunological synapse and synthesis thereof20US 10,907,274 B2Twist Bioscience Corporation · 2021